Loading
A phase 2 trial of Palbociclib, Fulvestrant, Letrozole in small-cell lung cancer and ovarian cancer, run by Pfizer, active and no longer recruiting.
PF-07104091 as a Single Agent and in Combination Therapy is a phase 2 interventional study registered as NCT04553133 by Pfizer, with 157 participants enrolled, started 2020-09-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC). Conditions listed: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palbociclib, Fulvestrant.
Shares Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Ovarian cancer.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Fulvestrant.
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares Palbociclib, Fulvestrant.
Shares Fulvestrant, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/